INCYTE CORPORATION Unrecognized Tax Benefits, Increase Resulting from Acquisition
INCYTE CORPORATION (INCY) reported Unrecognized Tax Benefits, Increase Resulting from Acquisition of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-10.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition · last filed 2026-02-10
- INCYTE CORPORATION unrecognized tax benefits, increase resulting from acquisition for the quarter ending 2024-12-31 was $14.00K.
- INCYTE CORPORATION unrecognized tax benefits, increase resulting from acquisition for the quarter ending 2024-09-30 was $300.00K.
- INCYTE CORPORATION unrecognized tax benefits, increase resulting from acquisition for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- INCYTE CORPORATION unrecognized tax benefits, increase resulting from acquisition for fiscal 2024 was $9.11M.
- INCYTE CORPORATION unrecognized tax benefits, increase resulting from acquisition for fiscal 2023 was $0.00.
- INCYTE CORPORATION unrecognized tax benefits, increase resulting from acquisition for fiscal 2016 was $570.00K.
| Period end | Unrecognized Tax Benefits, Increase Resulting from Acquisition 3 month | Unrecognized Tax Benefits, Increase Resulting from Acquisition 6 month | Unrecognized Tax Benefits, Increase Resulting from Acquisition 9 month | Unrecognized Tax Benefits, Increase Resulting from Acquisition 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-10 | |||
| 2024-12-31 | $14.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $314.00K derived: sum of 2 quarters · filed 2026-02-10 | $9.11M 10-K · filed 2026-02-10 | |
| 2024-09-30 | $300.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-29 | $9.10M 10-Q · filed 2024-10-29 | ||
| 2024-06-30 | $8.80M 10-Q · filed 2024-07-30 | |||
| 2023-12-31 | $0.00 10-K · filed 2025-02-10 | |||
| 2016-12-31 | $570.00K 10-K · filed 2018-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| IQVIA HOLDINGS INC. (IQV) | United States | $45.926B | 20.54 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B |